Metformin (K -Met SR (1000 mg)) is an oral antidiabetic agent, prescribed for type 2 diabetes. It helps control blood sugar levels. The information provided on this page is intended to serve as a ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE ™ XR (saxagliptin and metformin HCl extended-release), ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...

Please provide your email address to receive an email when new articles are posted on . Nostrum Laboratories, Inc., is voluntarily recalling two lots of metformin hydrochloride extended-release ...

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...

MENLO PARK, Calif. -- Depomed announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the 1000 mg strength tablets of GlumetzaTM (metformin hydrochloride ...

Three makers of Type 2 diabetes drug Metformin announced recalls Friday, the U.S. Food & Drug Administration reported. The reason for the voluntary recalls: the U.S. Food & Drug Administration ...

LINCOLNSHIRE, Ill., November 1, 2005 – Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met TM (pioglitazone HCl and metformin HCl) is now available by prescription in ...

One of the manufacturers of a Type 2 diabetes drug, Metformin Hydrochloride Extended-Release Tablets, extended its recall of its 500mg and 750 mg pills, the U.S. Food and Drug Administration reported ...

Janumet™ (MK-0431A) combines two OADs with complementary mechanisms of action to improve glycemic control, sitagliptin and metformin. The tablet was designed in order to be bioequivalent to ...

Canagliflozin and metformin combination products are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...